ConductScience.org, home

Paper8306044

Determinants of survival in idiopathic pulmonary fibrosis.

Schwartz DA and 7 others. Am J Respir Crit Care Med, 1994. Cited by 281 papers, by iCite.

Cite this record

ConductScience Library. Determinants of survival in idiopathic pulmonary fibrosis. Papers, record 8306044. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8306044

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Determinants of survival in idiopathic pulmonary fibrosis.
PubMed
Journal
Am J Respir Crit Care Med
PubMed
Year
1994
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
281
iCite
Relative citation ratio, by iCite
9.14
iCite
Revised in PubMed
2007-11-14
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schwartz DAD A
2Helmers RAR A
3Galvin JRJ R
4Van Fossen DSD S
5Frees KLK L
6Dayton CSC S
7Burmeister LFL F
8Hunninghake GWG W

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bronchoalveolar Lavage FluidMajor topic
Pulmonary FibrosisMajor topic
Female
Follow-Up Studies
Humans
Male
Middle Aged
Predictive Value of Tests
Prospective Studies
Regression Analysis
Sex Factors
Smoking
Spirometry
Survival Analysis
Time Factors

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
HL-37121NHLBI NIH HHSUnited StatesP50HL037121PubMed and NIHNIH RePORTER
OH00093-01NIOSH CDC HHSUnited StatesPubMedPubMed
RR-00059NCRR NIH HHSUnited StatesM01RR000059PubMed and NIHNIH RePORTER
K01OH000093NIHNIH RePORTER

Download CSV of grants

Cited by84

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 281 citations.

PMIDTitleJournalYearIn PapersSource
42706338Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.Nat Biotechnol2026https://conductscience.org/library/papers/42706338PubMed
41132946Exploring the Impact of Telerehabilitation on Physical Performance in Patients with Pulmonary Fibrosis.Telemed Rep2025https://conductscience.org/library/papers/41132946PubMed
40820275Age-related diseases as a testbed for anti-aging therapeutics: the case of idiopathic pulmonary fibrosis.Aging (Albany NY)2025https://conductscience.org/library/papers/40820275PubMed
40785882
What role does artificial intelligence-driven quantitative analysis of chest computed tomography play in providing pulmonary function for idiopathic pulmonary fibrosis patients undergoing pirfenidone treatment?
Quant Imaging Med Surg2025https://conductscience.org/library/papers/40785882PubMed
39855300Piezo2 Is a Key Mechanoreceptor in Lung Fibrosis that Drives Myofibroblast Differentiation.Am J Pathol2025https://conductscience.org/library/papers/39855300PubMed
39479511Revisiting the role of MicroRNAs in the pathogenesis of idiopathic pulmonary fibrosis.Front Cell Dev Biol2024https://conductscience.org/library/papers/39479511PubMed
38774483Effects of Natural Products through Inhibiting Endoplasmic Reticulum Stress on Attenuation of Idiopathic Pulmonary Fibrosis.Drug Des Devel Ther2024https://conductscience.org/library/papers/38774483PubMed
38384288Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan.Front Pharmacol2024https://conductscience.org/library/papers/38384288PubMed
38112764Deep learning-based prognostication in idiopathic pulmonary fibrosis using chest radiographs.Eur Radiol2024https://conductscience.org/library/papers/38112764PubMed
37883007Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan.Drugs Real World Outcomes2024https://conductscience.org/library/papers/37883007PubMed
37605652
Identifying oxidative stress-related biomarkers in idiopathic pulmonary fibrosis in the context of predictive, preventive, and personalized medicine using integrative omics approaches and machine-learning strategies.
EPMA J2023https://conductscience.org/library/papers/37605652PubMed
36550474Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume.Respir Res2022https://conductscience.org/library/papers/36550474PubMed
35782232Quantitative analysis of high-resolution computed tomography features of idiopathic pulmonary fibrosis: a structure-function correlation study.Quant Imaging Med Surg2022https://conductscience.org/library/papers/35782232PubMed
35548360Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis.Front Pharmacol2022https://conductscience.org/library/papers/35548360PubMed
35418487Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives.Eur Respir Rev2022https://conductscience.org/library/papers/35418487PubMed
34865413Prevalence and impact of airway diseases on clinical outcomes in idiopathic pulmonary fibrosis.Korean J Intern Med2022https://conductscience.org/library/papers/34865413PubMed
34685461A Soft Voting Ensemble-Based Model for the Early Prediction of Idiopathic Pulmonary Fibrosis (IPF) Disease Severity in Lungs Disease Patients.Life (Basel)2021https://conductscience.org/library/papers/34685461PubMed
34575245The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis.J Clin Med2021https://conductscience.org/library/papers/34575245PubMed
32853277Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.PLoS One2020https://conductscience.org/library/papers/32853277PubMed
32569216A score without diffusion capacity of the lung for carbon monoxide for estimating survival in idiopathic pulmonary fibrosis.Medicine (Baltimore)2020https://conductscience.org/library/papers/32569216PubMed

See all 84 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8306044

GET https://conductscience.org/api/papers/v1/8306044/cited_by?page=2